针对STAT3瘤性途径:癌症免疫疗法和药物重定位
Yushan Dong1, Jingyu Chen2, Yuhan Chen3
1Graduate School of Heilongjiang University of Chinese Medicine, No. 24, Heping Road, Xiangfang District, Harbin, Heilongjiang, China.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
|September 23, 2023
概括
针对信号传感器和转录3 (STAT3) 途径的激活器可以逆转免疫抑制瘤微环境. 这种方法通过恢复免疫细胞功能和抑制瘤生长来增强癌症免疫疗法.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 瘤微环境通常会抑制免疫反应,阻碍有效的癌症免疫疗法.
- 信号转换器和转录3激活器 (STAT3) 在创造这些免疫抑制条件和促进瘤进展方面发挥着关键作用.
研究的目的:
- 审查STAT3在瘤微环境中的免疫细胞调节中的多方面的作用.
- 探索针对癌症免疫疗法的STAT3途径的新型治疗策略.
主要方法:
- 关于研究STAT3在瘤发生和免疫调节中的作用的文献综述.
- 对新兴治疗方法的分析重点是抑制STAT3瘤性途径.
主要成果:
- STAT3显著影响各种免疫细胞种群,有助于瘤发展.
- 向STAT3是一个有希望的策略,可以克服免疫抑制并增强抗瘤免疫力.
结论:
- 调节STAT3通路为癌症免疫治疗提供了潜在的新途径.
- 对针对STAT3的药物和疗法的进一步研究是有必要的,以改善治疗结果.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Tumor Immunotherapy
551
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
551
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
The JAK-STAT Signaling Pathway
9.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.0K
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K


